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Abstract: 
Hypertension and dyslipidemia are two major risk factors for cardiovascular diseases and commonly occur 
together. Dyslipidemia is a primary,widely established as an independent major risk factor for coronary heart 
disease. Management of dyslipidemia in hypertension patients significantly decreases the total cardiovascular risk. 
Peroxisome proliferator-activated receptors [PPARs] belong to the nuclear family of ligand activated 
transcriptional factors and comprise three different isoforms, PPAR-𝛼, PPAR-𝛽/𝛿, and PPAR-𝛾. The main role of 
PPARs is to regulate the expression of genes involved in lipid and glucose metabolism. Several studies have 
demonstrated that PPAR agonists improve dyslipidemia and glucose control in animals, supporting their potential 
as a promising therapeutic option to treat diabetes and dyslipidemia. PPAR-𝛾, the best characterized of the PPARs, 
plays a crucial role in adipogenesis and insulin sensitization.Telmisartan, an angiotensin receptor blocker [ARB] 
that is highly selective for AT1 receptor has been found to be a PPAR-𝛼 agonist and a selective PPAR-G modulator. 
This unique action of telmisartan on PPAR leads to favourable effects on lipid and carbohydrates metabolism which 
is independent of BP lowering effect. This provides additional benefit in treatment of dyslipidemia. 
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INTRODUCTION: 
Hypertension 
Hypertension is defined by persistent elevation of 
arterial blood pressure [BP]. Patients with diastolic 
blood pressure [DBP] values <90 mm Hg and 
systolic blood pressure [SBP] values ≥140 mm Hg 
have isolated systolic hypertension.[1]  
 
Hypertension remains the most prevalent 
cardiovascular disease [CVD] risk factor and is 
present in ever-growing numbers worldwide.[2,3] In 
the United States hypertension affects over 30% of 
adults or approximately 76,400,000 [2008 data] men 
and women age 20 years. Data from the National 
Health and Nutrition Examination Survey indicate 
that approximately 8% of adults in the United States 
have undiagnosed hypertension, and of those 
diagnosed only three-quarters use antihypertensive 
medications. Among those taking medication, blood 
pressure [BP] is controlled in only half.[4] The 
societal and financial burden of hypertension is not 
likely to reverse soon as projections suggest a 10% 
increase in hypertension prevalence by the year 
2030.[5] These statistics are especially troubling 
when one considers the consequences of 
hypertension; elevated BP [140/90 mmHg] precedes 
myocardial infarction [MI], stroke, or congestive 
heart failure in 69% of cases.[6]  
 
In hypertensive individuals, there is a high 
prevalence of decreased level of high density 
lipoprotein [HDL], increased total cholesterol and 
elevated triglyceride [TG] levels as compared to 
normotensive individuals.[7] Hypertension is a 
common cardiovascular disease and coexists with 
conditions like dyslipidemia and ischemic heart 
disease. Elevated total cholesterol [TC] levels 
increase the risk of cardiovascular disease associated 
with hypertension and dyslipidaemia. When these 
two conditions coexist, it demands a strict emphasis 
on dietary and pharmacological therapy to achieve 
control on both successfully. Contrary to the goal, it 
is reported that only in 32% of hypertensive patients; 
lipid profile is improved, while this percentage falls 
to eleven for control of both blood pressures [BP] and 
lipids.[8] 
 
DYSLIPIDEMIA: 
Disorders of lipoprotein metabolism together with 
high fat diets, obesity and physical inactivity have all 
contributed to the current epidemic of atherosclerotic 
disease seen in developed countries. Disorders of 
lipoprotein metabolism that result in elevated serum 
concentrations of total cholesterol [TC] and low-
density lipoprotein cholesterol [LDL-C] increase the 
risk of an individual developing cardiovascular  
 
 
disease [CVD]. In contrast, high-density lipoprotein 
cholesterol [HDL-C] confers protection against CVD, 
with the risk reducing as HDL-C increases. It is, 
therefore, clear that the term hyperlipidaemia, which 
was formerly used to describe disorders of 
lipoprotein metabolism, is inappropriate. It is more 
appropriate to use the term dyslipidaemia, which 
encompasses both abnormally high levels of specific 
lipoproteins, for example, LDL-C, and abnormally 
low levels of other lipoproteins, for example, HDL-
C, as well as disorders in the composition of the 
various lipoprotein particles. It is particularly 
appropriate when considering the individual at risk of 
CVD with a normal or high TC and low HDL-C 
[total cholesterol:HDL-C ratio].[9] 
 
Up to 60% of the variability in cholesterol fasting 
lipids may be genetically determined, although 
expression is often influenced by interaction with 
environmental factors. The common familial 
[genetic] disorders can be classified as: 
 The primary hypercholesterolaemias such as 
familial hyper-cholesterolaemias in which 
LDL-C is raised. 
 The primary mixed [combined] 
hyperlipidaemias in which both LDL-C and 
triglycerides are raised. 
 The primary hypertriglyceridaemias such as 
type III hyperlipoproteinaemia, familial 
lipoprotein lipase deficiency and familial 
apoC-II deficiency.[9] 
 
Hypertension and hyperlipidemia commonly coexist. 
In hypertensive individuals, there is a high 
prevalence of decreased level of high density 
lipoprotein [HDL], increased total cholesterol and 
elevated triglyceride [TG] levels as compared to 
normotensive individuals.[10] Elevated total 
cholesterol [TC] levels increase the risk of 
cardiovascular disease associated with hypertension 
and dyslipidaemia. When these two conditions 
coexist, it demands a strict emphasis on dietary and 
pharmacological therapy to achieve control on both 
successfully. Contrary to the goal, it is reported that 
only in 32 % of hypertensive patients; lipid profile is 
improved, while this percentage falls to eleven for 
control of both blood pressures [BP] and lipids.[11] 
The antihypertensive drugs primarily affect the 
increased blood pressure without affecting the 
disordered lipid metabolism that often accompanies 
hypertension. Angiotensin II receptor blockers 
[ARBs] are efficient antihypertensive agents that act 
through inhibition of AT1 receptors.[12] 
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ANGIOTENSIN II RECEPTOR BLOCKERS 
Angiotensin II receptor antagonists [angiotensin 
receptor blockers [ARBs]] are widely used clinically 
as antihypertensive agents. In addition to reducing 
blood pressure [BP], ARBs attenuate cardiovascular 
risk via suppression of the reninangiotensin system 
[RAS] mediated by antagonism of the angiotensin II 
[AT1] receptor.[13] There are eight ARBs currently 
on the market for hypertension and in different 
cardiovascular indications, ie, losartan, valsartan, 
candesartan, eprosartan, irbesartan telmisartan, 
olmesartan, and azilsartan, All ARBs are approved 
for the treatment of hypertension. In addition, 
irbesartan and losartan are approved for diabetic 
nephropathy, losartan is approved for stroke 
prophylaxis, and valsartan and candesartan are 
approved for heart failure and to reduce 
cardiovascular mortality in clinically stable patients 
with left ventricular failure or left ventricular 
dysfunction following myocardial infarction. ARBs 
also demonstrated effectiveness in preventing 
atheromas, decreasing endothelial dysfunction, 
increasing fibrinolysis, reducing proteinuria, and 
preserving kidney function in diabetic patients.[14] 
 
TELMISARTAN 
Telmisartan is licensed for the treatment of essential 
hypertension. Telmisartan, a nonpeptide AT-II-
receptor antagonist, gained FDA approval for use in 
the treatment of hypertension in 1998. Peak plasma 
levels are obtained 0.5-1 hour after oral 
administration, and the plasma t1/2 is ~24 hours. Oral 
bioavailability of ARBs generally is low [<50%, 
except for irbesartan, with 70% available], and 
protein binding is high [>90%]. Telmisartan is 
cleared from the circulation mainly by biliary 
secretion of intact drug. The plasma clearance of 
telmisartan is affected by hepatic but not renal 
insufficiency.[15] The recommended oral dosage of 
telmisartan is 40-80 mg once daily. When further 
blood pressure reduction is needed [beyond that 
achieved with 80 mg/day], the addition of 
hydrochlorothiazide has been found to produce 
incremental reductions.[16] 
 
DRUG INTERACTIONS 
No interactions with drugs that inhibitor are 
metabolized by CYP isoenzymes would be expected, 
given that CYP isoenzymes are not involved in 
telmisartan’s metabolism, with the possible exception 
of interference with the metabolism of drugs 
metabolized by CYP2C19. When telmisartan is 
administered with digoxin, peak and trough plasma 
concentrations of digoxin are increased 49% and 
20%, respectively. When telmisartan is given with 
warfarin there is no evidence of any change in the 
International Normalized Ratio. 
 
ADVERSE EVENTS 
 The overall frequency of adverse events with 
telmisartan 20-160 mg/ day was reported to be 
similar to that with placebo. Rates of upper-
respiratory-tract infection [7%], dizziness [5%], back 
pain [3%], sinusitis [3%], and diarrhea [3%] were 
similar to the rates for placebo [6%, 6%, 1%, 3%, and 
2% respectively]. The rate of cough with telmisartan 
[15.6%] was comparable to that with placebo [9.6%] 
and significantly less than with lisinopril [60%].[16] 
 
Numerous studies have demonstrated that the 
peroxisome proliferator–activated receptor-𝛾 [PPAR-
𝛾] plays an important role in regulating carbohydrate 
and lipid metabolism and that ligands for PPAR-𝛾 
can improve insulin sensitivity, reduce triglyceride 
levels, and decrease the risk for atherosclerosis.[17] 
 
Peroxisome proliferator-activated receptors [PPAR] 
are nuclear hormone-activated receptors and 
transcription factors. To date, three different PPAR 
subtypes have been cloned and characterized: PPAR-
𝛼, PPAR-𝛽 and PPAR-𝛾 [18-21]. The ligands for 
PPAR have been demonstrated to include structurally 
diverse compounds that vary from industrial 
chemicals and pharmaceutical drugs to endogenous 
fatty acids. These ligands can induce enormous 
molecular and cellular changes, including 
peroxisome proliferation, adipogenesis, β-oxidation 
enhancement, and cell-cycle regulation. After a 
decade of intense study, much has been learned 
regarding the molecular mechanisms by which PPAR 
activation results in its biologic consequences. PPAR 
have been shown to be critical factors in regulating 
diverse biologic processes, including lipid 
metabolism, adipogenesis, insulin sensitivity, 
immune response, and cell growth and 
differentiation.[18-21] and participate in the 
pathogenesis of a cluster of human diseases 
designated the metabolic syndrome, which includes 
insulin resistance, glucose intolerance, obesity, 
dyslipidemia, hypertension, atherosclerosis, and 
micro-albuminuria.[22-24] 
 
Importantly, the fibrate class of PPAR-𝛼 agonists 
including fenofibrate and clofibrate are clinically 
proven lipid-lowering drugs [25], whereas the 
thiazolidinedione [TZD] class of PPAR-𝛾 ligands 
such as rosiglitazone [Avandia] and pioglitazone 
[Actos] have recently been introduced into clinical 
practice for treating hyperglycemia and insulin 
resistance in patients with type 2 diabetes [26]. 
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TISSUE EXPRESSION OF PPAR 
In general, PPAR-𝛼 is highly expressed in tissues that 
possess high mitochondrial and β-oxidation activity, 
including liver, renal cortex, intestine mucosa, and 
heart. Lower expression of PPAR-𝛼 is also observed 
in several other tissues. PPAR-𝛾 is highly enriched in 
adipose tissue, but lower expression levels have also 
been reported in urinary bladder, intestine, kidney, 
spleen, adrenal, heart, liver, lung, brain, and 
vasculature. Unlike PPAR-𝛼 and PPAR-𝛾, PPAR-𝛽/𝛿 
seems to be ubiquitously expressed at low levels in 
almost every tissue examined. In the kidney, PPAR-𝛼 
is highly abundant in the proximal tubules and 
medullary thick ascending limbs with much lower 
levels in glomerular mesangial cells [27,28]. 
 
MODE OF PPAR ACTION 
Upon binding their cognate ligands, the 
transcriptional activity of PPAR is altered. A 
conformational change in the PPAR/retinoid X 
receptor-A [RXR-A] dimer allows the heterodimer to 
bind to PPAR-response elements [PPRE] to activate 
gene transcription. PPRE generally consist of a 
directrepeat of hexameric core recognition elements 
spaced by 1 bp [DR1, 5'AGGTCANAGGTCA-3'] 
located in the promoter regions of target genes 
[Figure 1] [18]. After activation of the PPAR/RXR 
heterodimer at the PPRE, the PPAR/RXR-A complex 
can recruit diverse nuclear receptor co-factors that 
modulate transcriptional activity of PPAR and RXR-
A receptor heterodimer. These coactivators include 
cAMP response element- binding protein, PPAR-𝛾 
coactivators, cAMP response element-binding protein 
binding protein, and steroid receptor coactivator-1. 
Co-repressors such as nuclear receptor co-repressor 
and silencing mediator of retinoid acid and thyroid 
hormone receptor can modulate the transcriptional 
activity of PPAR by remodeling chromatin and 
establishing physical contacts with transcription 
initiation machinery. Therefore, multiple mechanisms 
are involved in controlling the transcription of PPAR 
target genes in a given cell or tissue. The expression 
level of PPAR receptors, the chemical properties and 
local concentrations of PPAR-specific ligands, and 
the availability of these co-factors all contribute to 
the biologic effect of PPAR activation or 
inactivation. [20,29]. 
 
 
 
Fig.1: Mode of PPAR Action 
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Unlike natural fatty acids, which are good substrates 
for P-oxidation, substituted fatty acids, which are not 
a substrate for P-oxidation, are more potent PPAR 
activators, suggesting that the degree of PPAR 
activation is inversely correlated with the rate of fatty 
acid P-degradation. Although these studies 
demonstrate that exogenous fatty acids activate 
PPAR, it is not clear whether the active form is the 
acid or the acyl-CoA thioester, the production of 
which is controlled by the enzyme acyl-CoA 
synthetase. These acyl-CoA derivatives are either 
stored as an intracellular acyl-CoA ester pool 
complexed with the acyl-CoA binding protein or 
utilized in various intracellular enzymatic pathways. 
The direct involvement of acyl-CoA derivatives in 
intracellular lipid metabolism [in contrast to free fatty 
acids], together with the finding that xenobiotic 
peroxisome proliferators also form acyl-CoA esters , 
suggests that acyl-CoAs may be PPAR activators 
and/or ligands.[30] 
 
Peroxisome proliferator-induced acyl-CoA synthetase 
activity generates acyl-CoA esters that are used 
predominantly for P-oxidation [31,32]. Due to the 
pronounced increase of peroxisomal P-oxidation, 
associated with a more moderate induction of 
mitochondrial P-oxidation, after treatment with 
peroxisome proliferators, less acyl-CoA esters should 
be available to be utilized for TG synthesis. A 
reduction in acetyl-coA carboxylase [33-35] and fatty 
acid synthase [36] activities will inhibit de novo fatty 
acid synthesis, further diminishing the intracellular 
fatty acid levels available for TG synthesis [37]. 
Moreover, peroxisome proliferators not only increase 
poxidation and decrease TG synthesis [38], but also 
decrease apoB and VLDL production and secretion 
[35, 39-40]. 
 
Telmisartan acts as a partial PPAR α agonist and 
induces PPAR α expression. Thus there is induction 
of hepatic ACSL1 [acyl coA synthetase long chain] 
and CPT1A [carnitine palmitoyl trransferase]. This 
causes significant decrease of triglyceride level. 
PPAR α in skeletal muscle is not affected by 
Telmisartan. Hence the myopathy associated with 
fibrates is not seen with Telmisartan. Thus PPAR α 
activation by Telmisartan is liver specific because of 
its specific pharmacokinetic Profile[41]  .  
 
DISCUSSION: 
Telmisartan is an angiotensin 2 type 1 receptor 
blocker, originally developed for the treatment of 
essential hypertension. It was also reported to 
partially activate the peroxisonme proliferator 
receptor gamma [PPAR- γ] which may improve 
insulin sensitivity and dysregulation of adipokine 
secretion. This activation of Telmisartan through 
PPAR- γ activation has additional benefit in the 
treatment of essential hypertension with 
dyslipidemia. Many animal studies have 
demonstrated the beneficial effects of telmisartan on 
obesity, accumulation of visceral adipose tissues, 
insulin sensitivity and fatty liver. 
 
PPARs are ligand activated transcription factors 
belonging to the super family of nuclear receptors. 
PPAR γ is abundantly expressed in adipose tissue and 
is a major regulator of insulin and glucose 
metabolism. In contrast, PPAR α is highly expressed 
in tissues displaying a high metabolic rate of fatty 
acids, such as the liver and skeletal muscle. PPAR α 
modulates intracellular lipid metabolism by 
transcriptional regulation of genes involved in fatty 
acid uptake, mitochondrial fatty acid oxidation and 
triglycerides catabolism. PPAR α is the molecular 
target of fibrates such as Gemfibrozil, etc. 
 
Telmisartan acts as a partial PPAR α agonist and 
induces PPAR α expression. Thus there is induction 
of hepatic ACSL1 [acyl coA synthetase long chain] 
and CPT1A [carnitine palmitoyl trransferase]. This 
causes significant decrease of triglyceride level. 
PPAR α in skeletal muscle is not affected by 
Telmisartan. Hence the myopathy associated with 
fibrates is not seen with Telmisartan. Thus PPAR α 
activation by Telmisartan is liver specific because of 
its specific pharmacokinetic Profile. 
 
It is widely believed that the currently available 
ARBs are metabolically neutral and have little or no 
impact on carbohydrate and lipid metabolism when 
administered in conventional doses used to treat 
hypertension. However, the current findings suggest 
that Telmisartan might be an exception in this regard 
and provide insight into new strategies for developing 
molecules that could improve many if not all of the 
biochemical and blood pressure disturbances that 
compose the metabolic syndrome. 
 
PPAR agonists convey beneficial effects as 
therapeutic agents for diabetes and atherosclerosis by 
lowering blood glucose, improving insulin resistance, 
inflammation, and lipid metabolism; however, 
adverse side effects limit their clinical use. As such, 
the future of PPAR-directed agents in cardio-
metabolic therapy remains uncertain, although 
several late-stage molecules may still hold promise. 
Future directions in PPAR agonist development are 
likely to focus on optimizing the PPAR subtype 
interaction profile, maximizing the inhibition of 
PPAR-𝛾 phosphorylation, and screening against off-
target activity. At the present time, clinicians should 
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keep in mind the risk/benefit ratio of PPAR 
activators. Intensive research on this therapeutic 
target will likely lead to the development of safer and 
more effective PPAR agonists in the near future.  
 
The multiple mechanisms of action of Telmisartan, 
including AT1 receptor blockade, PPAR γ 
modulation and hepatic PPAR α activation, 
characterizes this compound as a therapeutic option 
for the treatment of patients suffering from multiple 
cardio metabolic disorders such as hypertension, 
glucose intolerance, and dyslipidemia. 
 
CONCLUSION: 
Clinically, Telmisartan plays a major role in reducing 
the hypertension by blocking angiotension receptors. 
Now-a-days a large number of large scale clinical 
trials had proven that telmisartan not only reduces the 
blood pressure, but also it shows better improvement 
on most lipid indices, like increases in HDL and 
decreases in TC,TG,VLDL, and LDL. One of the 
possible explanations for such an improvement with 
telmisartan could be that it acts as a partial PPAR γ 
agonist. PPAR-γ regulates lipid metabolism and 
therefore reduces TG and LDL levels. 
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